

## **SANOFI PASTEUR OPENS \$100M R&D CENTRE IN CANADA**

### ***Strategic Canadian asset puts Ontario at the heart of global vaccine innovation***

TORONTO, June 21, 2011 /CNW Telbec/ - *The Lancet* just published the "New Decade of Vaccines" series where experts call for urgent action to make vaccine research a critical priority. Vaccine research and development is *the* priority for this North American Centre of Excellence. With over 95 years of vaccine innovation history, and \$100 million in new R&D investment, Sanofi Pasteur manufactures vaccines that are vital to public health - in Canada and around the world.

- Our country's *only* billion-dollar biotech product - the international gold standard for whooping cough prevention - researched, developed and manufactured in Toronto
- 94% of vaccines produced at this Toronto site are exported to over 90 countries
- 20% of sales at the world's largest vaccine company are generated by vaccines manufactured in Toronto

Sanofi Pasteur has over 95 years of history in Canada and now "Building 95" is getting ready to write the next 95 years of Canadian innovation.

Mr. Mark Lievonon, President of Sanofi Pasteur Limited, invites members of the media to attend the official opening of "Building 95" in the presence of Premier Dalton McGuinty and other special guests. A tour of Building 95 will be organized for the media.

#### **Reminder:**

**Who:** Premier Dalton McGuinty  
Monte Kwinter, Member of Provincial Parliament for York Centre  
Mark Lievonon, President, Sanofi Pasteur Limited

**What:** Official opening of R&D Centre - Building 95: A National Strategic Asset

**Where:** Sanofi Pasteur Limited  
1755 Steeles Avenue West  
Toronto, ON M2R 3T4

**When:** Wednesday, June 22, 2011  
10:00 am to 11:00 am (plan 10-15 minutes to clear security)

For further information:

or to schedule an interview contact:

Kristen King  
T 416-848-1427  
C 416-830-9933  
[kking@national.ca](mailto:kking@national.ca)

---